You are here: Home News Great achievement: the European Medecines Agengy adopted a positive scientific opinion of fexinidazole

Great achievement: the European Medecines Agengy adopted a positive scientific opinion of fexinidazole

We are very happy to share the great news that the European Medicines Agency has given a positive opinion under Article 58 for the use of fexinidazole to treat both stage-1 and stage-2 sleeping sickness:

https://www.dndi.org/2018/media-centre/press-releases/ema-recommends-fexinidazole-first-all-oral-treatment-sleeping-sickness/

Fexinidazole, developed by DNDi in partnership with Sanofi, is the first all-oral treatment for sleeping sickness and will support international efforts to eliminate the disease. PhinC Development is very proud to have taken part since 2009 in the “fexinidazole” story.

Dr Antoine Tarral, Head of the DNDi’ Human African Trypanosomiasis development program, said: "The PhinC Development team has accompanied us throughout this program. In particular, their expertise in pharmacokinetic modeling has enabled us to select the therapeutic dose and optimize the dose regimen. I most particularly appreciated their continuous involvement, their professionalism and their ability to work together with all the other actors involved in this program”.